Industry Revenues:

• Pharmaceutical Products: approx. 70%
• Animal Health: approx. 20%
• Other Business Areas: approx. 10%

TOP 3 Markets:

• China: approx. 60%
• Southeast Asia: approx. 20%
• Europe: approx. 10%

The United Laboratories International Holdings Limited generates the majority of its revenues from the manufacturing and distribution of pharmaceutical products. The Animal Health sector also contributes significantly to the revenue, while other business areas make up a smaller share.

China remains the company's main market, followed by Southeast Asia and Europe. These markets are crucial for the company's growth as they exhibit a strong demand for pharmaceutical products.

Production Sites: China

The United Laboratories International Holdings Limited produces the majority of its products in China. The company has several production facilities in different regions of China that specialize in the manufacturing of pharmaceutical products and active ingredients. This geographical concentration enables the company to benefit from the cost advantages and well-developed infrastructure in China.

Revenue Growth: Estimated 8-10% annually (2026)

Focus on R&D Investments: Increase by 15% (2025)

The United Laboratories International Holdings Limited pursues a growth strategy that heavily emphasizes research and development (R&D). The company has significantly increased its investments in R&D to develop innovative pharmaceutical products and expand its product pipeline. This is intended not only to strengthen competitiveness but also to tap into new market segments.

Another focus is on geographical expansion. The company plans to enhance its presence in emerging markets, particularly in Asia and Africa, where the demand for affordable medications is rising.

Additionally, the company is focusing on operational efficiency improvements to reduce production costs and enhance profit margins. This includes the modernization of production facilities and the implementation of advanced technologies for process automation and optimization.

Main raw materials: Antibiotic active ingredients, chemicals for pharmaceutical products
Countries of origin: China, India, Germany

The United Laboratories International Holdings Limited mainly imports active ingredients and chemicals needed for the production of antibiotics and other pharmaceutical products. China and India are the primary suppliers of these raw materials, as they are significant producers of pharmaceutical ingredients. Germany is also utilized as a source for specialized chemical components required for production.

This import strategy enables the company to benefit from the cost-effective production capacities in Asia while relying on the high quality and reliability of European suppliers.

Market share in China: 5.2% (2025, estimated)
R&D expenses: 8.5% of revenue (2025)
EBITDA margin: 18.7% (2025)

The United Laboratories International Holdings Limited has a significant competitive advantage in the Chinese pharmaceutical market, especially through its strong presence in the production of antibiotics. The company benefits from its vertically integrated production structure, which allows it to reduce costs and increase efficiency.

Another advantage is the continuous investment in research and development, which amounts to 8.5% of revenue. This supports the introduction of new products and enhances the existing product range, helping the company to differentiate itself from competitors.

The EBITDA margin of 18.7% indicates a solid profitability, reflecting efficient operations and a strong market position. Overall, the company's competitive advantage is well secured through its strategic investments and market position.

Institutional Investor Share: Estimated 35% (2026)
Insider Buys/Sells: No significant transactions reported (2026)

The institutional investor share in The United Laboratories International Holdings Limited is estimated to be around 35%. This suggests that a significant number of shares are held by large investors such as pension funds, investment funds, and other institutional investors.

In 2026, no significant insider buys or sells were reported. This could indicate that the management and other insiders have confidence in the current company strategy and the market value of the shares. However, it is important to regularly review this data to identify changes in ownership structure or management confidence.

Market share of The United Laboratories International Holdings Limited: Estimated 5% (2026)

Top competitors and their market shares:

1. Sinopharm Group Co. Ltd.: 15%
2. Shanghai Pharmaceuticals Holding Co. Ltd.: 12%
3. CSPC Pharmaceutical Group Limited: 10%
4. China Resources Pharmaceutical Group Limited: 8%
5. The United Laboratories International Holdings Limited: 5%
6. Sino Biopharmaceutical Limited: 4%
7. Hengrui Medicine: 3%
8. Fosun Pharma: 3%
9. Yunnan Baiyao Group Co., Ltd.: 2%
10. Harbin Pharmaceutical Group Co., Ltd.: 2%

Moat of The United Laboratories International Holdings Limited:

The United Laboratories International Holdings Limited has a moderate moat, mainly attributed to its production capacities and established distribution networks in China. The company benefits from vertical integration, allowing it to reduce costs and increase efficiency.

Compared to its competitors, Sinopharm has a stronger moat due to its extensive distribution network and greater product diversification. Shanghai Pharmaceuticals and CSPC Pharmaceutical Group also have significant advantages through their strong R&D pipelines and strategic partnerships.

Overall, the moat of The United Laboratories is less pronounced than that of some of its larger competitors, meaning it operates in a competitive market and must continuously invest in innovation and efficiency to maintain or expand its market position.

Revenue Growth: 8.5% (2025) Profit Growth: 10.2% (2025) Research and Development Ratio: 5.7% of revenue (2025)

The United Laboratories International Holdings Limited recorded a solid revenue growth of 8.5% in 2025, indicating stable demand for its pharmaceutical products. The profit growth of 10.2% shows that the company was able to increase its efficiency and benefit from cost savings.

Another positive aspect is the investment in research and development, which accounts for 5.7% of revenue. This suggests that the company is investing in innovations to expand its product range and remain competitive.

Overall, the company demonstrates a healthy financial performance and a commitment to future growth through innovation. These factors make the stock a potentially good investment, provided that market conditions remain stable and the company achieves its strategic goals.

Dividend Yield: Estimate 3.5% (2026)

The United Laboratories International Holdings Limited has regularly paid out dividends in the past. The dividend yield is estimated to be around 3.5% for 2026, based on the latest available financial reports and market analyses.

The reliability of dividend payments depends on the financial stability of the company. In recent years, the company has pursued a consistent dividend policy, indicating a certain level of reliability. However, analysts also monitor the overall market trends and the specific challenges in the pharmaceutical industry that could influence future dividend policies.